<a href="https://www.fiercebiotech.com/biotech/gsk-pens-1b-deal-chinas-siranbio-oligonucleotide-could-reduce-adominal-fat" hreflang="en">GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat</a>
GSK has entered a $1 billion deal with China's SiranBio for the rights to SA030, an oligonucleotide therapy in phase 1 development aimed at reducing abdominal fat and improving cardiometabolic health. The agreement includes an upfront payment of $55 million, milestone payments, and royalties, as GSK seeks to enhance its pipeline targeting obesity-related metabolic disorders.
GSK's $1 billion deal with China's SiranBio for the oligonucleotide SA030, targeting ALK7 to reduce abdominal fat, highlights the strategic shift towards oligonucleotide therapeutics in treating cardiometabolic diseases. This approach not only aims to address obesity but also potentially improves insulin sensitivity and reduces inflammation, offering opportunities for novel combination therapies. For a professional tracking healthtech, this signals a significant investment opportunity in oligonucleotide-driven therapies and the potential for strategic partnerships in precision medicine targeting metabolic disorders.